Patents by Inventor Annette Atkins
Annette Atkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101962Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.Type: ApplicationFiled: June 23, 2023Publication date: March 28, 2024Applicant: Salk Institute for Biological StudiesInventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
-
Patent number: 11760977Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.Type: GrantFiled: May 24, 2017Date of Patent: September 19, 2023Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
-
Patent number: 11685901Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.Type: GrantFiled: March 28, 2022Date of Patent: June 27, 2023Assignee: Salk Institute for Biological StudiesInventors: Ronald Evans, Michael Downes, Annette Atkins, Eiji Yoshihara, Ruth Yu
-
Publication number: 20230097335Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.Type: ApplicationFiled: December 2, 2022Publication date: March 30, 2023Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
-
Patent number: 11542309Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.Type: GrantFiled: July 15, 2020Date of Patent: January 3, 2023Assignee: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
-
Patent number: 11440889Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: September 1, 2020Date of Patent: September 13, 2022Assignees: The Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Publication number: 20220220446Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.Type: ApplicationFiled: March 28, 2022Publication date: July 14, 2022Applicant: Salk Institute for Biological StudiesInventors: Ronald EVANS, Michael DOWNES, Annette ATKINS, Eiji YOSHIHARA, Ruth YU
-
Patent number: 11376264Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.Type: GrantFiled: January 8, 2020Date of Patent: July 5, 2022Assignee: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
-
Publication number: 20210363490Abstract: The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.Type: ApplicationFiled: October 11, 2019Publication date: November 25, 2021Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Eiji YOSHIHARA, Ruth YU, Michael DOWNES, Ronald EVANS, Annette ATKINS
-
Publication number: 20210147365Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: ApplicationFiled: September 1, 2020Publication date: May 20, 2021Applicants: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
-
Publication number: 20210032303Abstract: The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.Type: ApplicationFiled: July 15, 2020Publication date: February 4, 2021Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sihao Liu, Ruth T. Yu
-
Patent number: 10815203Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: September 10, 2019Date of Patent: October 27, 2020Assignees: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Patent number: 10695404Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.Type: GrantFiled: April 13, 2018Date of Patent: June 30, 2020Assignee: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
-
Publication number: 20200129532Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.Type: ApplicationFiled: January 8, 2020Publication date: April 30, 2020Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
-
Publication number: 20200123113Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: ApplicationFiled: September 10, 2019Publication date: April 23, 2020Applicants: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
-
Publication number: 20200040051Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.Type: ApplicationFiled: October 24, 2019Publication date: February 6, 2020Applicants: Salk Institute for Biological Studies, The Florida State University Research Foundation, IncorporatedInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu, Michael Blaber, Xue Xia
-
Patent number: 10450277Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: November 27, 2018Date of Patent: October 22, 2019Assignees: The Salk Institute for Biological Studies, University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Publication number: 20190276510Abstract: The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof, as well as FGF1-vagus targeting chimeric proteins which include an FGF1 portion (e.g., native FGF1 or mutant FGF1) and a portion that targets the chimera to the vagus nerve (e.g., GLP or exendin-4). Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants and FGF1-vagus targeting chimeric proteins can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.Type: ApplicationFiled: May 22, 2019Publication date: September 12, 2019Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu, Sihao Liu
-
Publication number: 20190211310Abstract: The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.Type: ApplicationFiled: May 24, 2017Publication date: July 11, 2019Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: RONALD EVANS, MICHAEL DOWNES, ANNETTE ATKINS, EIJI YOSHIHARA, RUTH YU
-
Publication number: 20190192630Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: ApplicationFiled: March 7, 2019Publication date: June 27, 2019Applicant: Salk Institute for Biological StudiesInventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu